Chronic Conditions

Understanding Chronic Inflammatory Conditions

Chronic fatigue syndrome (ME/CFS), long COVID, and fibromyalgia share overlapping features: persistent fatigue, cognitive impairment (“brain fog”), pain, and post-exertional symptom worsening. While their triggers differ, emerging research suggests common pathophysiological mechanisms involving:

• Persistent immune activation — elevated inflammatory cytokines and autoantibodies
• Microclotting and endothelial dysfunction — impaired microcirculation affecting oxygen delivery
• Autoantibody formation — antibodies against cellular receptors disrupting normal signaling
• Neuroinflammation — inflammatory mediators crossing the blood-brain barrier

These circulating factors — antibodies, cytokines, microclots, and inflammatory mediators — are precisely what therapeutic plasma exchange can physically remove from the bloodstream.

Long COVID (Post-Acute Sequelae of SARS-CoV-2)

Long COVID affects an estimated 10-30% of people who contract SARS-CoV-2, with symptoms persisting months to years after initial infection. Common symptoms include debilitating fatigue, cognitive dysfunction, exercise intolerance, autonomic dysfunction, and persistent inflammation.

How TPE May Help

Research has identified several plasma-borne factors in long COVID patients:

• Autoantibodies — Anti-G protein-coupled receptor (GPCR) antibodies have been found at elevated levels, potentially disrupting autonomic function
• Persistent spike protein — Viral protein fragments may circulate for months, driving ongoing immune activation
• Microclots — Amyloid fibrin microclots resistant to normal fibrinolysis trap inflammatory molecules
• Elevated cytokines — IL-6, TNF-alpha, and other inflammatory markers remain elevated

TPE can physically remove these circulating pathogenic factors in a single treatment session, potentially breaking the cycle of immune activation.

Current Evidence

Multiple case series and pilot studies have reported symptom improvement in long COVID patients treated with TPE:

• Reductions in fatigue severity within days of treatment
• Improvement in cognitive function and “brain fog”
• Reduction in measurable inflammatory markers
• Improved exercise tolerance in previously bedbound patients

Important: While these reports are encouraging, large randomized controlled trials are still in progress. Evidence is currently at the case-series and pilot-study level. TPE for long COVID is considered off-label and emerging.

Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (ME/CFS)

ME/CFS is a complex, debilitating condition characterized by profound fatigue not improved by rest, post-exertional malaise (PEM), cognitive dysfunction, unrefreshing sleep, and orthostatic intolerance. The condition affects an estimated 1-2.5 million Americans.

The Autoantibody Hypothesis

Research from Charité University in Berlin identified elevated autoantibodies against beta-2 adrenergic receptors and M3/M4 muscarinic acetylcholine receptors in ME/CFS patients. These autoantibodies may impair:

• Blood vessel regulation (contributing to orthostatic intolerance)
• Heart rate variability
• Cognitive function
• Energy metabolism

Immunoadsorption (a targeted form of apheresis) reduced these antibody levels and produced symptom improvement in a subset of patients in pilot studies.

TPE Rationale for ME/CFS

TPE removes the full spectrum of circulating antibodies and inflammatory mediators rather than targeting a single antibody type. For patients with:

• Documented autoantibodies against adrenergic/muscarinic receptors
• Elevated inflammatory markers despite standard treatment
• Post-infectious onset (suggesting immune-triggered pathology)

TPE may offer a pathway to reduce the antibody and inflammatory burden contributing to symptoms.

Current Evidence Level

Evidence for TPE in ME/CFS is at the pilot-study and case-report level. Clinical trials using immunoadsorption (a related technique) have shown promise, but large-scale randomized trials specific to TPE are needed. This is considered an emerging indication.

Fibromyalgia

Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction. While traditionally considered a central sensitization disorder, recent research has identified peripheral immune components:

• Small fiber neuropathy — up to 50% of fibromyalgia patients show small nerve fiber pathology on biopsy
• Autoantibodies — A landmark 2021 study (Goebel et al.) demonstrated that transferring IgG antibodies from fibromyalgia patients to mice reproduced pain sensitivity and reduced small fiber density, proving an antibody-mediated component
• Neuroinflammation — PET imaging studies show activated microglia in fibromyalgia patients

The Goebel Study Significance

The finding that fibromyalgia IgG antibodies alone can transfer the condition to animals represents a paradigm shift — it identifies a removable plasma component directly causing symptoms. This provides strong mechanistic rationale for TPE, though clinical trials are still needed.

Current Evidence Level

Direct clinical trial evidence for TPE in fibromyalgia is limited. However, the demonstrated autoantibody-mediated mechanism provides scientific rationale, and case reports describe symptom improvement following TPE in selected patients. This is considered an off-label or emerging indication.

What TPE Can and Cannot Do for Chronic Conditions

What TPE can do:

• Physically remove circulating autoantibodies, cytokines, and inflammatory proteins
• Potentially break cycles of immune activation
• Provide relatively rapid (days) changes in plasma composition
• Be repeated if initial treatment shows benefit

What TPE cannot do:

• Cure the underlying condition
• Prevent antibody regeneration without complementary immune-modulating therapy
• Address tissue damage that has already occurred
• Replace standard medical care (exercise, sleep optimization, pacing strategies)

Our Approach

1. Thorough evaluation
2. Transparent evidence discussion
3. Individualized protocol
4. Outcome tracking
5. Coordination

Next Steps

If you have long COVID, ME/CFS, fibromyalgia, or another chronic condition involving persistent inflammation, and standard treatments have been insufficient, request a consultation to discuss whether TPE may be appropriate for your situation.